Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

Bittner, Vera; Szarek, Michael; Aylward, Philip E.; Bhatt, Deepak L.; Díaz, Rafael; Edelberg, Jay M.; Fras, Zlatko; Goodman, Shaun G.; Halvorsen, Sigrun; Hanotin, Corinne; Harrington, Robert A.; Jukema, J. Wouter; Loizeau, Virginie; Moriarty, Patrick M.; Moryusef, Angèle; Pordy, Robert; Roe, Matthew T.; Sinnaeve, Peter; Tsimikas, Sotirios; Vogel, Robert A.; White, Harvey D.; Zahger, Doron; Zeiher, Andreas M.; Steg, Philippe Gabríel; Schwartz, Gregory G.

doi:10.1016/j.jacc.2019.10.057

articleJournal of the American College of CardiologyJan 1, 2020HYBRID OA

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

VBVera Bittner MSMichael Szarek PEPhilip E. Aylward DLDeepak L. Bhatt RDRafael Díaz

University of Alabama at Birmingham · State University of New York · +35 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

Background

Lipoprotein(a) concentration is associated with cardiovascular events. Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C).

Objectives

A pre-specified analysis of the placebo-controlled ODYSSEY Outcomes trial in patients with recent acute coronary syndrome (ACS) determined whether alirocumab-induced changes in lipoprotein(a) and LDL-C independently predicted major adverse cardiovascular events (MACE).

Citation impact

567

total citations

FWCI: 62.28
Percentile: 100%
References: 32

Citations per year

Authors

25

Topics & keywords

Topics

Keywords

Medicine
Alirocumab
Acute coronary syndrome
Cardiology
Internal medicine
Lipoprotein(a)
Lipoprotein
Cholesterol

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.